Press-release for stocks related to n/a for MRTX

Prices are updated after-hours

tags : N::A symbols : MRTX

save search

Corcept Appoints Roberto Vieira as President, Oncology
Published: 2024-01-29 (Crawled : 13:00) - globenewswire.com
CORT M | $23.0 -1.67% -1.7% 960K

Health Technology

| 7.99% | O: 0.6% H: 2.48% C: 2.48%

European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
Published: 2024-01-10 (Crawled : 13:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| -0.31% | O: 0.02% H: 0.17% C: -0.19%
krasg12 lung cancer cell treatment advanced

Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
Published: 2023-11-10 (Crawled : 12:30) - prnewswire.com
BMY | $47.84 -0.87% -0.02% 12M

Health Technology

| -4.27% | O: 0.4% H: 0.18% C: 0.0%
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 4.61% | O: -0.11% H: 0.0% C: 0.0%
krasg12 lung chmp positive cancer cell treatment therapeutics

Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
Published: 2023-11-07 (Crawled : 21:00) - globenewswire.com
GNMSF | $285.11 3.83% 420

Health Technology

| -3.35% | O: 6.62% H: 2.29% C: -0.06%
ZLAB | $13.75 -4.65% -4.87% 400K

Health Technology

| -51.54% | O: 8.3% H: 0.02% C: -2.12%
SGEN | $228.74 0.1% 20M

Health Technology

| 6.91% | O: 0.49% H: 0.0% C: -0.57%
NVCR | $12.04 -3.37% -3.49% 1.4M

Health Technology

| -6.37% | O: 0.7% H: 0.0% C: -6.94%
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 4.89% | O: 0.29% H: 0.21% C: -0.48%
KRTX | $329.83 0.0% 1.9M

Health Technology

| 83.73% | O: 0.27% H: 0.14% C: -3.34%
GMAB | $28.51 -3.13% -3.23% 360K

Health Technology

| -3.35% | O: 7.35% H: 0.44% C: -2.18%
results

Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
Published: 2023-11-02 (Crawled : 12:00) - globenewswire.com
BMY | $47.84 -0.87% -0.02% 12M

Health Technology

| -5.89% | O: -0.9% H: 1.08% C: 0.61%
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 5.41% | O: 0.2% H: 0.43% C: -0.38%
KURA | $18.0 -3.17% -3.28% 660K

Health Technology

| 125.16% | O: 0.13% H: 6.0% C: 5.25%
ko-2806 collaboration therapeutics agreement

Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)
Published: 2023-10-17 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 3.98% | O: -0.04% H: 0.35% C: -0.53%
lung cancer cell results

Pancreatic Cancer Battle Boosted by $200M VC Firm
Published: 2023-09-19 (Crawled : 17:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K

Health Technology

| -46.08% | O: -1.47% H: 4.98% C: 3.98%
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 84.91% | O: -0.13% H: 2.0% C: 1.83%
MACK 4 | $14.68 0.0% 100K

Health Technology

| 19.93% | O: -0.41% H: 0.9% C: 0.74%
INCY | $52.74 -0.9% -0.91% 2.5M

Health Technology

| -11.41% | O: 0.03% H: 2.18% C: 1.8%
BNTX | $86.42 0.09% 0.09% 1.2M

Health Technology

| -20.82% | O: -0.01% H: 1.99% C: 1.28%
cancer pancreatic

Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer
Published: 2023-09-10 (Crawled : 04:20) - prnewswire.com
MS | News | $90.08 1.06% -0.28% 9.5M

Finance

| Email alert Add to watchlist
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| Email alert Add to watchlist
lung conference world cancer response study

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Published: 2023-09-05 (Crawled : 20:00) - prnewswire.com
MS | News | $90.08 1.06% -0.28% 9.5M

Finance

| 5.17% | O: -1.87% H: 0.0% C: 0.0%
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 64.44% | O: 0.36% H: 0.86% C: -1.17%
nasdaq grant therapeutics

Mirati Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
Published: 2023-08-29 (Crawled : 20:00) - prnewswire.com
MS | News | $90.08 1.06% -0.28% 9.5M

Finance

| 6.87% | O: 1.44% H: 0.0% C: 0.0%
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 61.37% | O: 0.69% H: 1.04% C: 1.01%
conference global therapeutics

Mirati To Present Pooled Clinical Data from Adagrasib's KRYSTAL-1 Study Demonstrating Overall Survival Results at Two-Years of Follow-Up at 2023 World Conference on Lung Cancer
Published: 2023-08-21 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 55.36% | O: 0.5% H: 1.29% C: -1.02%
lung conference world cancer results study

Mirati Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Published: 2023-08-11 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| Email alert Add to watchlist
offering therapeutics

Mirati Therapeutics Announces Pricing of Upsized Public Offering
Published: 2023-08-09 (Crawled : 05:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 109.7% | O: 23.42% H: 8.46% C: 6.87%
offering therapeutics

Mirati Therapeutics® to Report Second Quarter 2023 Financial Results and Recent Corporate Updates on August 8, 2023
Published: 2023-07-25 (Crawled : 21:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 92.47% | O: 0.29% H: 0.0% C: -2.19%
therapeutics report financial results

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation
Published: 2023-07-21 (Crawled : 12:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 73.97% | O: -14.97% H: 11.97% C: 8.9%
lung review update cancer cell treatment therapeutics

Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director
Published: 2023-06-23 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| Email alert Add to watchlist
therapeutics

Mirati To Encore Compelling Clinical Data Demonstrating Adagrasib's Potential as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors at 2023 ASCO Annual Meeting
Published: 2023-05-30 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 58.54% | O: 0.43% H: 2.55% C: -0.27%
krasg12 asco tumors treatment meeting potential

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO®
Published: 2023-05-24 (Crawled : 20:00) - prnewswire.com
BMY | $47.84 -0.87% -0.02% 12M

Health Technology

| -26.29% | O: -0.81% H: 0.32% C: -0.59%
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 34.17% | O: -6.18% H: 0.0% C: -6.64%
opdivo update sapphire therapeutics study

Zai Lab Announces First Quarter 2023 Financial Results and Corporate Updates
Published: 2023-05-09 (Crawled : 20:00) - globenewswire.com
ABBV | $164.25 1.05% -0.76% 4M

Health Technology